Clinical Trial

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Study acronym: GUIDANCE
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-16; most recent amendment 2025-05-14.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-12-19
Trial Details
NCT Number NCT06419179
Lead Sponsor University of Cologne
Collaborators: AstraZeneca
Conditions Small Cell Lung Carcinoma
Enrollment 29 participants
Start Date 2024-10-09
Primary Completion 2026-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-20